Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000050

Drug Information
NameIdarubicin
Synonyms5,12-Naphthacenedione, 7,8,9,10-tetrahydro-9-acetyl-7-((3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy)-6,9,11-trihydroxy-, (7S-cis)-; 4-DMD; Lopac0_000600; NCGC00093976-02; DMDR; Idarubicine [INN-French]; 57852-57-0 (HYDROCHLORIDE); SMR000466355; NCGC00093976-01; 4-Demethoxydaunomycin; Idamycin; CID42890; 4-Demethoxydaunorubicin; KBioSS_002388; 4-Desmethoxydaunorubicin; IMI-30; DB01177; 57852-57-0; CHEBI:42068; I1656_SIGMA; UNII-ZRP63D75JW; Zavedos (TN); Idarubicina; Idarubicinum; IDARUBICIN; Zavedos; idarubicin hydrochloride; EU-0100600; I06-1097; Idarubicin Hcl; LS-94015; 5,12-Naphthacenedione, 9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S-cis)-; MLS000759470; NCGC00093976-04; Daunomycin, 4-demethoxy-; NSC-256439; 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-6,9,11-trihydroxy-, (7S-cis)-; Idarubicinum [INN-Latin]; BRD-K69650333-001-01-1; Idarubicine; Idarubicina [INN-Spanish]; AC1Q6JJ4; NSC256439; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-|A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; D08062; IMI 30; (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; AC1L28SA; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; CCRIS 5083; CHEMBL1117; Idarubicin [INN:BAN]; DM5; C26H27NO9; Idarubicin (INN); I 1656; 58957-92-9; HMS2089D05; NCGC00093976-03; Idarubicin Hcl Pfs
Trade NameZavedos; Idamycin
CompanyBen Venue Laboratories, Inc
IndicationAcute myeloid leukemia
[ICD9: 205.0   ICD10: C92.0]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8
-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3
-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/
m0/s1
InChIKeyXDXDZDZNSLXDNA-TZNDIEGXSA-N
Canonical SMILESCC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)
N)O    
Isomeric SMILESC[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C(=C23)O)C(=O)C5=
CC=CC=C5C4=O)O)(C(=O)C)O)N)O
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 58957-92-9
FormulaC26H27NO9
PubChem Compound IDCID 42890.
PubChem Substance IDSID 183368.
ChEBI42068;
SuperDrug ATC IDL01DB06
SuperDrug CAS ID058957929;
TargetDNA topoisomerase IIInhibitor[2]
Ref 1New drugs for the treatment of cancer, 1990-2001. Isr Med Assoc J. 2002 Dec;4(12):1124-31. To Reference
Ref 2Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells. Biochem Pharmacol. 2002 May 15;63(10):1807-15. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543